Chemoradiotherapy Before Surgery May Improve Outcomes in Resectable Pancreatic Cancer
Evidence suggests that neoadjuvant chemoradiotherapy may afford benefit, but this hypothesis requires further validation.
Diagnosis & Disease Information
Bevacizumab Plus Erlotinib May Be a New Standard of Care in Non-Small Cell Lung Cancer
Recent studies have explored the potential of combination therapy with EGFR-TKIs and VEGF-inhibitors for patients with EGFR-positive non-small cell lung cancer.
Gefitinib Plus Platinum-Doublet Chemotherapy May Improve Overall Survival in EGFR-Positive NSCLC
EGFR tyrosine kinase inhibitor monotherapy has improved progression-free survival (PFS) but not overall survival (OS) compared with chemotherapy in non-small cell lung cancer.
Abiraterone for mCRPC May Benefit Patients Who Are Black More Than Patients Who Are White
Abiraterone plus prednisone was associated with significantly greater PSA progression-free survival among patients who are black compared with white patients.
PET/CT Accurately Localizes Recurrent Prostate Cancer
Salvage therapy guided by 68Ga-PSMA11 PET/CT resulted in high biochemical response rates.
Post-Radiotherapy Docetaxel for Intermediate-, High-Risk Prostate Cancer Is Not Beneficial
A phase 3 trial involving men treated with radiotherapy for intermediate- or high-risk prostate cancer revealed no significant difference in biochemical disease-free survival.
Complete Lymph Node Dissection May Not Improve Outcomes in Melanoma
When compared with watchful waiting, CLND did not improve survival outcomes among patients with malignant melanoma who have positive SLNB.
Long-Term Data Show Nivolumab May Provide Sustained Benefit Compared With Ipilimumab
Preliminary findings from CheckMate 238 show treatment with nivolumab significantly prolonged recurrence-free survival compared with ipilimumab in patients with resected stage III/IV melanoma after a minimum 18-month follow-up.
Prostate Cancer Vaccine Found Not To Improve Survival
In a phase 3 trial, Prostvac-V/F did not significantly prolong overall survival among men with asymptomatic or minimally symptomatic mCRPC.
Abiraterone Plus Leuprolide Offers Edge in M0 Hormone-Naive Prostate Cancer
Abiraterone plus leuprolide compared with leuprolide decreased the risk of biochemical recurrence by 38%.
- Loading...
Loading...
Next post in ASCO 2018
Loading... 
Loading...